Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVOSKIN PSMC is a topical cream formulated primarily from Évaux thermal spring water, which is naturally rich in lithium, developed for the prevention and management of hand-foot syndrome (HFS) associated with chemotherapy, particularly oral capecitabine. Its mechanism of action is not fully elucidated, but its utility arises from its moisturizing and soothing properties, which help dissipate erythema, relieve pain, and reduce blistering and peeling in affected patients. EVOSKIN PSMC has been evaluated for reducing the incidence and severity of HFS in cancer patients undergoing capecitabine chemotherapy, showing a statistically significant reduction in severe HFS compared to physiological saline cream[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EVOSKIN PSMC.